Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

HB 1765Sesión 2025

Qué cambió entre versiones

22 párrafos cambiaron+240 palabras agregadas−64 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

OFFERED FOR CONSIDERATION

1/14/2025

2025 SESSION

INTRODUCED

25103143D

HBHOUSE BILL NO. 1765

SUBCOMMITTEE

1. After line 22, introduced

insert

2. That the provisions of this act shall apply to any individual or group accident and sickness insurance policy, individual or group accident and sickness subscription contract, or health care plan for health care services delivered, issued for delivery, or renewed in the Commonwealth on and after January 1, 2026.

Offered January 13, 2025

Prefiled January 5, 2025

A BILL to amend the Code of Virginia by adding a section numbered 38.2-3407.9:06, relating to health insurance; coverage for non-opioid prescription drugs.

—————

Patron—Martinez

—————

Referred to Committee on Labor and Commerce

—————

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding a section numbered 38.2-3407.9:06 as follows:

§ 38.2-3407.9:0 6 . Coverage for non-opioid prescription drugs .

No (i) insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical , and surgical or major medical coverage on an expense-incurred basis ; (ii) corporation providing individual or group accident and sickness subscription contracts ; or (iii) health maintenance organization providing a health care plan for health care services whose policy, contract , or plan, including any certificate or evidence of coverage issued in connection with such policy, contract , or plan, includes coverage for prescription drugs shall impose any cost-sharing, prior authorization, step therapy, or other limitation on coverage of a covered non-opioid drug approved by the U.S. Food and Drug Administration for the treatment or management of pain that is more restrictive or less favorable to the enrollee relative to a covered opioid drug approved by the U.S. Food and Drug Administration for the treatment or management of pain .

Volver al texto completo